Shuyang Zhu

机构：Xuzhou Medical College, Second Military Medical University, Eastern Hepatobiliary Surgery Hospital · ORCID：0000-0002-9998-6476

发表论文 58 篇 · 总被引 703 次 · h-index 11

代表论文

• Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study (2022 · The Lancet Respiratory Medicine · 被引 236)
• Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study (2022 · Journal of Thoracic Oncology · 被引 79)
• Nonenzymatic lysine d-lactylation induced by glyoxalase II substrate SLG dampens inflammatory immune responses (2025 · Cell Research · 被引 72)
• Empagliflozin improves renal ischemia–reperfusion injury by reducing inflammation and enhancing mitochondrial fusion through AMPK–OPA1 pathway promotion (2023 · Cellular & Molecular Biology Letters · 被引 56)
• A Double-Blind Randomized Placebo-Controlled Phase 3 Trial of Tobramycin Inhalation Solution in Adults With Bronchiectasis With Pseudomonas aeruginosa Infection (2022 · CHEST Journal · 被引 49)
• Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial (2021 · 癌症：英文版 · 被引 26)